

Title (en)  
TREATMENT OF ESOPHAGEAL CANCER

Publication  
**EP 0572563 A4 19931229 (EN)**

Application  
**EP 92908199 A 19920207**

Priority  
US 65893691 A 19910221

Abstract (en)  
[origin: WO9214470A1] A method of treating esophageal cancer in a human afflicted therewith which comprises administering to such human an effective amount of a compound of the water soluble camptothecin analog class.

IPC 1-7  
**A61K 31/535**

IPC 8 full level  
**A61K 31/47** (2006.01); **A61K 31/495** (2006.01); **A61K 31/535** (2006.01); **A61P 35/00** (2006.01); **C07D 491/22** (2006.01)

CPC (source: EP KR)  
**A61K 31/47** (2013.01 - EP); **A61K 31/495** (2013.01 - EP); **A61K 31/535** (2013.01 - EP KR); **A61P 35/00** (2017.12 - EP)

Citation (search report)

- [DX] EP 0321122 A2 19890621 - SMITHKLINE BECKMAN CORP [US]
- [A] C.G. MOERTEL ET AL: "Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer.", CANCER CHEMOTHER REP., vol. 56, no. 1, 1972, pages 95 - 101
- [A] M.R. MATTERN ET AL: "Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor SKF 104864.", PROC. AM. ASSOC. CANCER RES. ANNU. MEET., vol. 31, 1990, pages 436
- [A] Y. OHE ET AL: "Pharmacokinetics with a 5-day continuous infusion of a camptothecin derivative, CPT-11.", PROC. ANNU. MEET. AM. SOC. CLIN. ONCOL., vol. 10, 1991, pages 117
- See references of WO 9214470A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

DOCDB simple family (publication)  
**WO 9214470 A1 19920903**; AU 1540692 A 19920915; AU 664172 B2 19951109; CA 2104449 A1 19920822; EP 0572563 A1 19931208; EP 0572563 A4 19931229; JP H06505487 A 19940623; KR 930702985 A 19931129; MX 9200725 A 19920901; PT 100154 A 19930531

DOCDB simple family (application)  
**US 9201029 W 19920207**; AU 1540692 A 19920207; CA 2104449 A 19920207; EP 92908199 A 19920207; JP 50780792 A 19920207; KR 930702492 A 19930820; MX 9200725 A 19920221; PT 10015492 A 19920221